SBRT, Useful for Treating Mesothelioma, to be Discussed at 2010 ASTRO Conference
Stereotactic Body Radiation Therapy (SBRT) technology, used in the treatment of non-small cell lung cancer and mesothelioma, will be highlighted at the American Society for Radiation Oncology (ASTRO) conference to be held October 31-November 4 in San Diego. ASTRO has accepted four abstracts from users of Elekta SBRT technology for the treatment of non-small cell lung cancer (NSCLC).
“The research in which our Lung Cancer Consortium is engaged is completely consistent with ASTRO’s theme this year: Gathering Evidence; Proving Value,” says Joel Goldwein, M.D., Senior Vice President and Director of Medical Affairs for Elekta.
Elekta is a human care company, based in Sweden, pioneering innovations and clinical solutions for treating cancer and brain disorders. They are the world leader in image guided and stereotactic clinical solutions for radiosurgery and radiation therapy allowing radiation oncologists and neurosurgeons to treat tumors with ultra-high precision while sparing healthy tissue.
Pleural Mesothelioma is a form of lung cancer that is almost always caused by asbestos exposure and is most commonly found in the outer lining of the lungs called the mesothelium. Mesothelioma often has a complex growth pattern making surgery and radiation therapy difficult since pinpointing the malignant cells is difficult. Elekta’s latest technology enables highly accurate treatments that are fine-tuned to treat cancer and avoid healthy tissues.
NSCLC is the most common form of lung cancer, and is caused by smoking, passive smoking (secondhand smoke), asbestos and radon exposure. Lung cancer is the leading cause of cancer death in men and women with 93,000 men and 80,000 women affected each year in the United States.
3,000 people in the United States are diagnosed each year with mesothelioma.